15 September 2022 | News
The APAC region represents 42 per cent (61) of the 144 new clinical trials started this year
Image credit: shutterstock
The Asia Pacific (APAC) region has taken in the lead in cell and gene clinical trials, accounting for the largest share of new trials during the first half of 2022, reveals the Alliance of Regenerative Medicine’s latest report mapping the sector’s progress.
The APAC region represents 42 per cent (61) of the 144 new clinical trials started this year, and includes a healthy number early in the pipeline (30); 26 in phase 2, and 5 in phase 3. The European pipeline has slowed “to a trickle” with 16 new clinical trials started in H1 2022, however, is the only region that is bottom-heavy.
By region, North America leads with 808 active clinical trials, followed by Asia Pacific with 640 trials, Europe with 329, and 88 active trials in all other regions.
Cell therapies make up the largest category of ongoing trials (968, 46%), followed by cell-based immuno-oncology (CBIO) (721, 34%) and gene therapies (372, 18%). Tissue-engineered therapies comprise the remaining 32 (2%) of ongoing clinical trials in the cell and gene therapy sector.